Differences in AT2-receptor stimulation between AT1-receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP

Journal of Hypertension

Volumn 20, Issue 6, 2002, Pages 1157-1163

  Siragy, Helmy M ^a   El Kersh, Mohamed A ^a   De Gasparo, Marc ^a   Webb, Randy L ^a   Carey, Robert M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Angiotensin II; Angiotensin II receptor blocker; AT2 receptor; Bradykinin; Losartan; Valsartan

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BRADYKININ; CYCLIC GMP; DRUG METABOLITE; LOSARTAN; VALSARTAN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; DRUG DERIVATIVE; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ADOLESCENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; FEMALE; INTERSTITIAL FLUID; KIDNEY; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RECEPTOR UPREGULATION; TISSUE LEVEL; ANIMAL; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG ANTAGONISM; EXTRACELLULAR SPACE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CYCLIC GMP; EXTRACELLULAR SPACE; FEMALE; IMIDAZOLES; INJECTIONS, INTRAVENOUS; KIDNEY; LOSARTAN; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VALINE;

EID: 0036591596     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200206000-00028     Document Type: Article

References (37)

1. International union of pharmacology. XXIII. The angiotensin II receptors
2. Addressing those two that go together: The Angiotensin II receptors and their role in blood-flow regulation
3. Action of angiotensin receptor subtypes on the renal tubules and vasculature: Implications for volume homeostasis and atherosclerosis
4. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril
5. Valsartan: Long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension
6. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the Losartan Heart Failure Survival Study ELITE II
7. Angiotensin peptides and inducible transcription factors
8. Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk
9. Angiotensin II and nitric oxide: A question of balance
10. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors
11. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation
12. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3′,5′-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats
13. The subtype 2 angiotensin receptor regulates renal prostaglandin F2 alpha formation in conscious rats
14. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats
15. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats
16. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism
17. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats
18. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: An active metabolite of DuP 753, an orally active antihypertensive agent
19. Preclinical pharmacology of angiotensin II receptor antagonists: Update and outstanding issues
20. Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype
21. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors
22. Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring
23. Bradykinin B2 receptor modulates renal prostaglandin E2 and nitric oxide
24. In vivo pharmacology of DuP 753
25. Validation in awake rats of a tail-cuff method for measuring systolic pressure
26. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids
27. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II
28. Prolonged angiotensin II antagonism in spontaneously hypertensive rats. Hemodynamic and biochemical consequences
29. Binding of valsartan to mammalian angiotensin AT1 receptors
30. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects
31. Pharmacological properties of angiotensin II receptor antagonists
32. Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin II antagonist
33. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor
34. Renal interstitial cGMP mediates natriuresis by direct tubule mechanism
35. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors
36. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist
37. The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects